News

Hanmi Pharmaceutical’s sales in the first half of this year were ₩ 549.6 billion…3.4%↑YoY.

2021.08.20



Hanmi Pharmaceutical reported ₩549.6 billion in sales in the first half of this year in the 2021 August Consolidated Semi-Annual Financial Report, an increase of 3.4% YoY (₩18 billion).

During this period, operating profit increased by 16.4% (₩6.5 billion) to ₩45.8 billion YoY, and net profit was ₩31.5 billion YoY, up 82.0% (₩14.2 billion).

In the first half of 2021, SG&A expenses increased by 9.6% (₩15.3 billion) to ₩174.7 billion YoY and SAE Ratio increased by 1.8%p to 31.8% YoY.

Retail sales of competitors’ products were ₩43.7 billion, down 11.3% YoY (-₩5.6 billion), and ROS was 8.0%, down 1.3%p YoY.

R&D expenses decreased by 28.9% YoY (-₩2.9 billion) to ₩72.8 billion, and the R&D to sales ratio was 13.2%, a decrease of 6.0%p YoY.

Overseas sales/exports increased by 6.8% YoY (₩11.8 billion) to ₩186.8 billion, and the overseas sales/exports to sales ratio was 34.0%, up 1.1%p YoY.

Sales in the second quarter of 2021 were ₩279.3 billion, up 14.7% YoY (₩35.9 billion), and up 3.3% QoQ (₩9 billion).

Operating profit in the second quarter was ₩15.9 billion, up 49.6% YoY (₩5.3 billion), and down 47.0% QoQ (-₩14.1 billion). Net profit was ₩8.3 billion, up 43.1% YoY (₩2.5 billion), and down 64.4% QoQ (₩15 billion).

During this period, SG&A expenses increased by 20.0% YoY (₩15 billion) to ₩89.9 billion, and 6.1% QoQ (₩5.1 billion). Product sales decreased by 10.4% YoY (-₩2.7 billion) to ₩23.2 billion, and increased by 12.7% QoQ (₩2.6 billion).

R&D expenses decreased by 20.1% YoY (-₩9.7 billion) to ₩38.6 billion, and increased by 12.9% QoQ (₩4.4 billion). Overseas sales and exports were ₩88.9 billion, up 22.9% YoY (₩16.6 billion) and down 9.1% QoQ (-₩9 billion).

Source: Yakup